)
Summit Therapeutics (SMMT) investor relations material
Summit Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Ivonescimab programs span NSCLC, colorectal, urothelial, renal and biliary tract cancers, with additional solid-tumor collaborations.
AstraZeneca’s $2.0 billion investment closed Oct. 5, supporting accelerated development; Sept. 30 cash, cash equivalents and short-term investments totaled $629.8 million.
Akeso-reported Phase III studies showed OS benefits in PD-L1-positive NSCLC and biliary tract cancer.
Financial highlights
Q3 GAAP operating expenses were $214.6 million vs. $234.2 million YoY; R&D was $169.1 million vs. $131.1 million, while G&A was $45.5 million vs. $103.1 million.
Q3 GAAP net loss was $208.4 million, or $0.26 per share, vs. $231.8 million, or $0.31 per share; non-GAAP net loss was $160.7 million, or $0.20 per share.
Nine-month GAAP operating expenses were $630.3 million vs. $869.5 million; net loss was $613.5 million, or $0.78 per share, vs. $860.4 million, or $1.16 per share.
Outlook and guidance
HARMONI’s PDUFA action date was Nov. 14, 2026; a conference call was planned following FDA action.
HARMONI-3 squamous-cohort primary PFS analysis and early OS interim were expected in Q4 2026; non-squamous PFS events were expected in H1 2027.
HARMONI-GI3 enrollment was expected to complete in Q3 2027; HARMONI-7 enrollment was expected to complete in 2027.
Initial Arcus-collaboration data for casdatifan in clear-cell RCC were expected by mid-2027; further global Phase III expansion was planned.
R&D and G&A expenses were expected to rise as clinical development, infrastructure and headcount expand.
- Shareholders approved doubling authorized common shares to 2 billion.SMMT
EGM 2026 - A proposed doubling of authorized shares would support preferred conversion and future financing, with dilution risks.SMMT
Proxy filing - A 1 billion-share authorization increase is tied to a $2 billion preferred financing.SMMT
Proxy filing - Ivonescimab's phase III successes position it as a potential game changer in solid tumor therapy.SMMT
The Citizens Life Sciences Conference 2026 - Ivonescimab achieved landmark Phase III survival results, FDA BLA acceptance, and strong cash reserves.SMMT
Q2 2026 - Ivonescimab shows superior efficacy and safety in NSCLC, driving global phase III trials.SMMT
Citi's 2024 Global Healthcare Conference - Ivonescimab's strong phase III data drive BLA plans, but urgent new funding is needed.SMMT
Q3 2025 - Ivonescimab's strong Phase III results and $487M cash drive global clinical expansion.SMMT
Q3 2024 - Ivonescimab's PFS benefit and China approval drive global trials, with $361M cash and no debt.SMMT
Q1 2025
Next Summit Therapeutics earnings date
Next Summit Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)